Jeff Lazarus and Jörn Schattenberg join the Surfers to discuss their new Innovations in NAFLD Care 2022 webinar and hybrid meeting series in a session whose dialogue blends medical, economic and public health discussions.
This episode uses quotes from Surfing the NASH Tsunami’s NASH-TAG 2022 coverage and comments from Roger Green to explore what we learned there about combination therapies.
Donna Cryer and Scott Friedman share perspectives on where all things NASH and NAFLD are heading in a conversation with Roger Green.
NASH-TAG 2022 Wrap-Up: Finding New Disease Insights and Reconsidering Clinical Trial Design
Key Opinion Leaders Convene to Discuss Their Impressions from the First Day of NASH-TAG 2022.
Learn about the drug development content at NASH-TAG 2022
This episode focuses on the importance of NASH cirrhosis clinical trials. The conversation addresses the general issue or cirrhosis and reviews the REVERSE study.
Jörn Schattenberg and Mazen Noureddin join the Surfers to discuss five recently-reported or ongoing clinical trials in NASH cirrhosis.
Manal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap NAFLD and NASH-related insights from the 2020 TLMdX, the AASLD annual liver meeting. This conversation focuses on issues that will increase the richness of our understanding of disease and predictions for TLM 2022 (Hopefully not Digital only!)
Manal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap this week’s just-concluded the AASDL 2021 TLMdX annual liver meeting.
